Intravenous Immunoglobulin (IVIG) Formulations Market: Increasing Incidences of Autoimmune Diseases to Push Demand in the Coming Years
With its successful first formulation that gained approval from the FDA in 1980, the concept of intravenous immunoglobulin (IVIG) received significant traction worldwide. Proven its worth in treating chronic metabolic disorders including multiple sclerosis, ITP (Immune Thrombocytopenia), Kawasaki syndrome and autoimmune hemolytic anemia, intravenous immunoglobulin (IVIG) has witnessed high adoption in the recent years, given the increasing prevalence of these disorders. Several such insights on intravenous immunoglobulin (IVIG) market have been slated in a new report titled "Intravenous Immunoglobulin (IVIG)...
View full press release